Pre-Conference Programs • November 7 – 8

Wednesday, Nov. 7, 2018

Immune Escape: Current Understanding of Mechanisms and Advances in Therapeutics Approaches

2 – 8 p.m.

As the categories and number of immunotherapies in clinical practice diversified, it became evident that renewed efforts to characterize and address mechanisms of primary immune resistance and secondary treatment failures are needed. This forum will cover current mechanistic understanding of pre-existing and acquired mechanisms of immune resistance to interventions such as immune checkpoint blockade and CAR T cell therapy, with a focus on tumor microenvironment.

Learn More »

Thursday, Nov. 8, 2018

Primer on Tumor Immunology and Cancer Immunotherapy™

8 a.m. – 5 p.m.

Our understanding of cancer immunobiology has increased dramatically in recent years, leading to the successful development of novel immune-based treatment options to improve cancer patient outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer.

Learn More »

Workshop on Nutrition, Metabolism and the Microbiome in Cancer Therapy

8 a.m. – 1 p.m.

Over the past few years, a multidimensional network of functional connections between the gut microbiome, intestinal physiology, whole-body metabolism, the immune system and neoplastic disease has emerged and recent progress has been marked by methodological advances that allowed to describe the impact of individual bacterial species on the intestinal barrier and organism-wide immune responses. This program will present major advances reported in 2016-2017 and future prospects of the microbiome space in cancer therapy.

Learn More »

Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials Workshop

2 – 6 p.m.

This workshop is intended to identify best practices for design, conduct, data collection, and analysis of clinical trials evaluating tumor measurement based efficacy endpoints for cancer immunotherapeutics and to engage with leaders in academia, industry, international regulatory, and patient groups. Numerous studies have been reported in the literature in an effort to improve upon conventional response criteria for tumor measurement based efficacy endpoints for cancer immunotherapeutics as conventional response criteria may not fully capture the benefit of this product class. 

Learn More »

Grant Writing: From Start to Finish, and Then Starting Again

6:30 – 8:30 p.m.

This program will encompass when and how to find the right grant for your career stage and project, the do’s and don’ts of grant writing and how to revise a grant for resubmission. Faculty members from academia with a track record of successful funding as well as program officers at the National Institutes of Health (NIH) will provide insight on writing effective grants and utilizing program officers in the revision stages to successfully obtaining funding.

Learn More »